Webinars
Watch now!
New webinar featuring
Dr. Joseph Vassalotti
Chief Medical Officer, National Kidney Foundation
Diabetic Kidney Disease
Importance of Diagnosis and Early Risk
Assessment for Optimal Outcomes
It’s not just analytics.
It’s Bioprognosis™.
Renalytix is seeking FDA De Novo marketing authorization for KidneyIntelX. The test is not FDA approved nor cleared for any use at this time. KidneyIntelX yields a custom risk score that identifies which adult diabetic patients in early stages of chronic kidney disease are at low, intermediate or high risk for rapid progressive decline in kidney function within a period of up to five years. To report a product concern or suspected Adverse Event, please contact Renalytix Client Service at 1-888.203.2725.
© Renalytix.
Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data.